Review
Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
François Bouzom,
Kathryn Ball,
Nathalie Perdaems,
Bernard Walther,
Corresponding Author
François Bouzom
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France.
E-mail: [email protected]
Search for more papers by this authorKathryn Ball
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France
Search for more papers by this authorNathalie Perdaems
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France
Search for more papers by this authorBernard Walther
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France
Search for more papers by this authorFrançois Bouzom,
Kathryn Ball,
Nathalie Perdaems,
Bernard Walther,
Corresponding Author
François Bouzom
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France.
E-mail: [email protected]
Search for more papers by this authorKathryn Ball
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France
Search for more papers by this authorNathalie Perdaems
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France
Search for more papers by this authorBernard Walther
Technologie Servier, 25/27 rue E. Vignat, 45000 Orleans, France
Search for more papers by this authorABSTRACT
In 2005, a survey compared a number of commercial PBPK software available at the time, mainly focusing on ‘ready to use’ modelling tools. Since then, these tools and software have been further developed and improved to allow modellers to perform WB-PBPK modelling including ADME processes at a high level of sophistication. This review presents a comparison of the features, values and limitations of both the ‘ready to use’ software and of the traditional user customizable software that are frequently used for the building and use of PBPK models, as well as the challenges associated with the various modelling approaches regarding their current and future use. PBPK models continue to be used more and more frequently during the drug development process since they represent a quantitative, physiologically realistic platform with which to simulate and predict the impact of various potential scenarios on the pharmacokinetics and pharmacodynamics of drugs. The ‘ready to use’ PBPK software has been a major factor in the increasing use of PBPK modelling in the pharmaceutical industry, opening up the PBPK approach to a broader range of users. The challenge is now to educate and to train scientists and modellers to ensure their appropriate understanding of the assumptions and the limitations linked both to the physiological framework of the ‘virtual body’ and to the scaling methodology from in vitro to in vivo (IVIVE). Copyright © 2012 John Wiley & Sons, Ltd.
References
- 1 The FDA website. http://fda.gov/AboutFDA/Transparency/Basics/ [August 2011]
- 2 A knoll by Krishan Maggon. http://knol.google.com/k/krishan-maggon/new-drug-approvals_fda_ema_2011/ [August 2011]
- 3 The Boeing website. http://www.boeing.com/history/boeing/777.html [August 2011]
- 4 Breimer DD, Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The ‘wooden shoe’ paradigm. Clin Pharmacokinet 1997; 32: 259–267.
- 5 Lesko LJ, Rowland M, Peck CC, et al. Optimizing the science of drug development opportunities for better candidate selection and accelerated evaluation in humans. Eur J Pharm Sci 2000; 10: iv–xiv.
- 6 Derendorf H, Lesko LJ, Chaikin P, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 2000; 40: 1399–1418.
- 7 Bellissant E, Courcier-Duplantier S, Blin O. Role of pharmacokinetic-pharmacodynamic relationships in drug development. Therapie 2002; 57: 347–357.
- 8 Dingemanse J, Appel-Dingemanse S. Integrated pharmacokinetics and pharmacodynamics in drug development. Clin Pharmacokinet 2007; 46: 713–737.
- 9 Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS PharmSci 2004; 6: E6–E12.
- 10 Yang RSH, Clewell HJ III, Andersen ME. Introduction: a historical perspective of the development and applications of PBPK models. In Physiologically Based Pharmacokinetic Modelling. MB Reddy (ed). John Wiley & Sons, Inc.: New York, 2005.
- 11 Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42: 883–908.
- 12 Nestorov I. Whole body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007; 3: 235–249.
- 13 De Buck S, Mackie C. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin Drug Metab Toxicol 2007; 3: 865–878.
- 14 Bouzom F, Walther B. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling. Fund Clin Pharmacol 2008; 22: 579–587.
- 15 Espié P, Tytgat D, Sargentini-Maier ML, Poggesi I, Watelet JB. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 2009; 41: 391–407.
- 16 Perdaems N, Blasco H, Vinson C, et al. Predictions of metabolic drug–drug interactions using physiologically based modelling. Clin Pharmacokinet 2010; 49: 239–258.
- 17 Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. An Rev Pharmacol Toxicol 2011; 51: 45–73.
- 18 Khalil F, Läer S. Physiologically based pharmacokinetics modelling: methodology, applications and limitations with a focus on its role in pediatric drug development. J Biomed Biotechnol 2011; June. doi:10.1155/2011/907461.
- 19 Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modelling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259–267.
- 20 Schmitt W, Willmann S. Physiology-based pharmacokinetic modelling: ready to be used. Drug Discov Today Tech 2005; 2: 125–132.
- 21 Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up’ vs ‘top-down’ recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53–75.
- 22 Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model. Biosilico 2003; 1: 121–124.
- 23 Jones H, Parrott N, Jorga K, Lavé T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006; 45: 511–542.
- 24 Pang KS, Rowland M. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the ‘well-stirred’ model over the ‘parallel tube’ model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 1977; 5: 655–680.
- 25 Ito K, Houston B. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 2004; 21: 785–792.
- 26 Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215–236.
- 27 Fan J, Chen S, Chow E, Pang KS. PBPK modelling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. Curr Drug Metab 2010; 11: 743–761.
- 28 Watanabe T, Kusuhara H, Sugiyama Y. Application of physiologically based pharmacokinetic modeling and clearance concept to drug showing transporter-mediated distribution and clearance in humans. J Pharmacokinet Pharmacodyn 2010; 37: 575–590.
- 29 Paine SW, Parker AJ, Gardiner P, Webborn PJH, Riley RJ. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 2008; 36: 1365–1374.
- 30 Pang KS, Durk MR. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn 2010; 37: 591–615.
- 31 Jamei M, Turner D, Yang JS, et al. Population based mechanistic prediction of oral absorption. AAPS J 2009; 11: 225–237.
- 32 Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50(Suppl 1): S41–S67.
- 33 Willman S, Schmitt W, Keldenich J, Lippert J, Dressman JB. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004; 47: 4022–4031.
- 34 Parrott N, Lave T. Applications of physiologically based absorption models in drug discovery and development. Mol Pharm 2008; 5: 760–775.
- 35 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093–1095.
- 36 Brown RP, Delp MD, Lindstedt SL, et al. Physiological parameters values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407–487.
- 37 Fagerholm U. Prediction of human pharmacokinetics: evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 2007; 59: 803–828.
- 38 Fagerholm U. Prediction of human pharmacokinetics - renal metabolic and excretion clearance. J Pharm Pharmacol 2007; 59: 1463–1471.
- 39 Fagerholm U. Prediction of human pharmacokinetics – gut-wall metabolism. J Pharm Pharmacol 2007; 59: 1335–1343.
- 40 Fagerholm U. Prediction of human pharmacokinetics: gastrointestinal absorption. J Pharm Pharmacol 2007; 59: 905–916.
- 41 Fagerholm U. Prediction of human pharmacokinetics: evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol 2007; 59: 1181–1190.
- 42 Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009; 328: 652–662.
- 43 Tachibana T, Kitamura S, Kato M, et al. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 2010; 27: 442–446.
- 44 Sun H, Pang KS. Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates. Pharm Res 2010; 27: 1237–1254.
- 45 Grime K, Webborn PJH, Riley RJ. Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes. Drug Metab Dispos 2008; 36: 1670–1678.
- 46 Gardiner P, Paine SW. The impact of hepatic uptake on the pharmacokinetics of organic anions. Drug Metab Dispos 2011; 39: 1930–1938.
- 47 Kuentz M, Nick S, Parrott N, Röthlisberger D. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 2006; 27: 91–99.
- 48
Kersting G,
Willmann S,
Würthwein G,
Lippert J,
Boos J,
Hempel G. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Cancer Chemoth Pharm 2011 Jul doi:10.1007/s00280-011-1706-9 [Epub ahead of print].
10.1007/s00280-011-1706-9 Google Scholar
- 49 Rowland Yeo K, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut – the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 2010; 39: 298–309.
- 50 Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010; 49: 189–206.
- 51 Germani M, Crivori P, Rocchetti M, et al. Evaluation of basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. J Pharm Sci 2007; 31: 190–201.
- 52 Rostami-Hodjegan A, Tucker GT. ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug-drug interactions. Drug Discov Today 2004; 1: 441–448.
- 53 Edginton AN, Willmann S. Physiology-based simulation of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet 2008; 47: 743–752.
- 54 Poulin P, Jones HM, Jones RDO, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 1. Goals, properties of the PhRMA dataset and comparison with literature datasets. J Pharm Sci 2011 May 3. doi:10.1002/jps.22554 [Epub ahead of print].
- 55 Jones HM, Jones RDO, Rowland M, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 2. Comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 2011 May 3. doi:10.1002/jps.22553 [Epub ahead of print].
- 56 Ring B, Chien JY, Adkison KK, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 3. Comparative assessment of prediction methods of human clearance. J Pharm Sci 2011 May 3. doi:10.1002/jps.22552 [Epub ahead of print].
- 57 Vuppugalla R, Marathe P, He H, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 4. Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 2011 May 3. doi:10.1002/jps.22551 [Epub ahead of print].
- 58 Poulin P, Jones HM, Jones RDO, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 5. Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the physiologically based pharmacokinetic (PBPK) approach. J Pharm Sci 2011 May 3. doi:10.1002/jps.22550 [Epub ahead of print].
- 59 Rowland M, Benet LZ. Lead PK commentary: Predicting human pharmacokinetics. J Pharm Sci 2011 May 31. doi:10.1002/jps.22637 [Epub ahead of print].
